��������

Yonghong Bai is currently a Director and Principal Scientist at MOMA Therapeutics and a Consultant at Third Rock Ventures. Prior to this, they worked at Amgen as a Senior Scientist and Group Lead from 2015 to 2020, where they provided structural biology and protein biochemistry support for drug discovery programs and determined 3.0-Å cryo-EM structure of the TRPC6 ion channel. Yonghong also supervised a direct report's structural biology efforts, determined a 2.3-Å cryo-EM structure of the GlyR⍋ ion channel, provided structural support for medicinal chemistry efforts, and built cryo-EM infrastructure. Before Amgen, they were a Postdoctoral Associate at Baylor College of Medicine from 2013 to 2015, a Postdoc Research Scientist at Columbia University in the City of New York from 2012 to 2013, and a Graduate Research Assistant at the University of Missouri-Columbia from 2007 to 2012.

Yonghong Bai received a Bachelor of Science in Biomedical Engineering from Zhejiang University in 2007 and a PhD in Bioengineering from the University of Missouri-Columbia in 2012.